LIANYOTCPharmaceutical PreparationsFiscal year ends December 31

LianBio

Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q on Nov 13, 2023

$0.06+0.01 (+15.10%)

Close on Oct 19, 2026

Market cap: $6.29M
P/E (TTM): –
Dividend yield: –

LianBio income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Research & Development	60	159	121
General & Administrative	66	37	14
Operating Expenses	125	196	135
Operating Income	-125	-196	-135
Other Non-Operating Income	10	-0.46	0.12
Pretax Income	-111	-196	-140
Income Tax Expense	-0.33	0.52	0.00
Minority Interest in Earnings	0	0	0
Net Income	-110	-196	-140
Preferred Dividends	0	0	0
EPS (Basic)(per share)	-1.02	-5.71	-11.58
EPS (Diluted)(per share)	-1.02	-5.71	-11.58
Shares Outstanding (Basic, Weighted)(shares)	108	34	12
Shares Outstanding (Diluted, Weighted)(shares)	108	34	12
Net Interest Income	4.32	0.24	-4.85

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2023

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2022: -36.0%

Financial strength

Current ratio: 10.06
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 403.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.03
Dividend yield: –